← Back to all signals
RESEARCH PAPER ANALYSIS

The effects of dabrafenib and/or trametinib treatment in Braf V600-mutant glioma: a systematic review and meta-analysis.

AI interpretation is pending for this paper.

Open original publication →
PMID39172230
JournalNeurosurgical review
Publication Date2024-08-22
Ingested2026-08-02 12:02 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

This study aimed to evaluate the effects of dabrafenib and/or trametinib therapy in BRAF v600-mutant glioma treatment. PubMed, the Cochrane Library, EMBASE and Web of Science were searched from inception to Sep 2023. Inclusion criteria were designed based on the PICO principle to select relevant articles. Search keywords included 'dabrafenib', 'trametinib', 'glioma' and other related keywords. Outcomes included overall survival (OS), progression-free survival (PFS), adverse events (AEs), and death events. Methodological index for non-randomized studies (MINORS) was used to assess the methodological quality. Stata 14.0 was selected to perform the Cochrane Q and I2 statistics to test the heterogeneity among all studies. As for publication bias assessment and sensitivity analysis, the funnel plot, Egger regression test, Begg test, and trim and fill method were selected. Including 8 studies for meta-analysis. The pooled results of the single-arm trials showed that the median PFS and median OS after treatment were 6.10 months and 22.73 months, respectively. Notably, this study found a high incidence of AEs and death events of 50% and 43% after treatment. All the above findings were statistically significant. Also, this study statistically supported the advantage of disease response improvement after the combination therapy in BRAF v600-mutant glioma patients, which were shown as a pooled rate of PR (30%), a pooled rate of CR (18%), and a pooled rate of ORR (39%). And the AE rate was lower in the monotherapy group (AE: 25%) than in the combination treatment group (AE: 60%). Sensitivity analysis indicated that all the results were robust. Based on current literature outcomes, dabrafenib and/or trametinib may lead to the median PFS of 6.10 months and median OS as 22.73 months for BRAF v600-mutant glioma patients, and the safety of monotherapy is better than that of combination therapy. This conclusion needs to be treated with caution and further verified.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The Journey with paediatric cancer: reflections on its impact on patients and their families. The Pan African medical journal 56.0 2 Pars plana vitrectomy in uveitis of diverse etiologies: indications and surgical outcomes. BMC ophthalmology 63.5 3 Persistent Oropharyngeal Hemangioma Causing Progressive Upper Airway Compromise: Diagnostic and Therapeutic Challenges. Cureus 61.64 4 Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma. ESMO open 71.84 5 Life Saving Hepatic Resections in Ruptured Pediatric Hepatoblastoma - a Report of 3 Cases. Indian journal of surgical oncology 63.6 6 Development and Internal Validation of the SPR-HCC Score System: A Prognostic Tool for Survival Prediction in Hepatocellular Carcinoma in a Resource-Limited Setting. Asian Pacific journal of cancer prevention : APJCP 72.02 7 Retinoblastoma Incidence in Saudi Arabia: A 20-Year Analysis. Asian Pacific journal of cancer prevention : APJCP 57.5 8 Systemic Immune Inflammation Index as High-Risk Retinoblastoma Survival Predictor. Asian Pacific journal of cancer prevention : APJCP 63.12 9 Predictors of Cervical Cancer Screening Uptake Among Women of Reproductive Age in Indonesia: A Nationwide Cross-Sectional Study Based on the 2023 Indonesian Health Survey. Asian Pacific journal of cancer prevention : APJCP 67.5 10 Effects of estetrol/drospirenone vs drospirenone-only on thrombin generation in women with polycystic ovary syndrome: a randomized, double-blind, controlled trial. Research and practice in thrombosis and haemostasis 77.6 11 Quality indicators for the care of children with CNS tumors: An international modified Delphi study. Neuro-oncology advances 72.0 12 Feasibility, uptake, and exploratory outcomes of an individualized exercise program in pediatric oncology: a prospective single-center pilot study. Frontiers in pediatrics 64.1 13 Prenatal diagnosis and outcomes of fetal cardiac tumors: a 10-year single-center study of 81 cases. Frontiers in medicine 66.0 14 Advances in the association between tumor immune microenvironment remodeling in osteosarcoma and the risk of pathological fractures. Frontiers in genetics 54.3 15 Proximal Phalanx Enchondroma in a Pediatric Patient: Curettage, Liquid Nitrogen Cryotherapy, Iliac Crest Autograft, and Microfragment Plate Fixation. Cureus 61.64 16 Beyond size: the role of growth rate in managing adolescent breast masses. American journal of surgery 68.5 17 Primary ovarian non-small cell neuroendocrine carcinoma in an adolescent: The youngest case reported to date. Pathology, research and practice 45.5 18 Indocyanine Green (ICG) fluorescence-Guided Surgery (FGS) in pediatric Wilms tumor: Opportunities and Challenges. Surgical oncology 47.5 19 Targeting SUV4-20H2-mediated H4K20 methylation restrains growth and migration in pediatric high-grade astrocytomas. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 62.2 20 Timing of breast cancer diagnosis postpartum and survival in women with germline pathogenic variants. ESMO open 71.02 21 Myxoid Pleomorphic Liposarcoma: A Clinicopathological and Cytogenomic Study of 24 Cases. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 60.7 22 Astragaloside IV is associated with TFRC-dependent ferroptosis and JAK2/STAT3 pathway inhibition in osteosarcoma cells. Biochimica et biophysica acta. General subjects 68.5 23 Purely osteolytic bone lesions in the early osteoarticular phase of synovitis, acne, pustulosis, hyperostosis and osteitis syndrome. BMJ case reports 54.0 24 Spatial Lineage Divergence at Diagnosis in a Pediatric KMT2A-Rearranged Leukemia Presenting with Concurrent AML and B-LBL. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 53.9 25 Temporary Perineal Urethrostomy for Bladder Tumor Resection. Case reports in urology 45.5 26 Public support for policies to create a healthier food environment in Aotearoa New Zealand: findings from a national survey. The New Zealand medical journal 65.2 27 The public in Aotearoa New Zealand support policies to reduce alcohol harm: results from a national survey. The New Zealand medical journal 66.5 28 Public support for government-led skin cancer prevention in Aotearoa New Zealand: findings from a national survey. The New Zealand medical journal 66.6 29 Public support for better controls on lobbying and industry influence in Aotearoa New Zealand: findings from a national survey. The New Zealand medical journal 43.2 30 Aotearoa New Zealanders' views of policies and funding for human papillomavirus vaccination and screening for cervical and lung cancers: a national survey. The New Zealand medical journal 66.4 31 Aotearoa New Zealand public strongly support investment in cancer treatment and care services: findings from a national survey. The New Zealand medical journal 66.94 32 Public support for cancer prevention and care policies in Aotearoa New Zealand: methods of a national survey. The New Zealand medical journal 66.9
PATIENT-FRIENDLY SUMMARY

The effects of dabrafenib and/or trametinib treatment in Braf V600-mutant glioma: a systematic review and meta-analysis.

For education only—not personal medical advice.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic